Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma.
Morton, Colin A ; Whitehurst, Colin ; McColl, John H ; Moore, James V ; MacKie, Rona M
Morton, Colin A
Whitehurst, Colin
McColl, John H
Moore, James V
MacKie, Rona M
Citations
Altmetric:
Abstract
BACKGROUND: Photodynamic therapy (PDT) using topical delta-aminolevulinic acid (delta-ALA) is an effective treatment for Bowen disease and certain basal cell carcinomas (BCCs), but its place in clinical practice remains to be established. Patients with large and/or multiple lesions of Bowen disease or BCC can represent a considerable therapeutic challenge. We suggest that delta-ALA PDT may be of particular benefit in such patients. OBSERVATION: In an open study, 35 (88%) of 40 large patches of Bowen disease, all with a maximum diameter greater than 20 mm, cleared following 1 to 3 treatments of delta-ALA PDT, although 4 patches recurred within 12 months. delta-Aminolevulinic acid PDT was also used to treat 40 large BCCs, with an identical 88% initial clearance (after 1-3 treatments), with 4 recurrences within 34 months (range, 12-60 months). In 10 further patients with multiple (> or =3) patches of Bowen disease, 44 (98%) of 45 patches cleared following delta-ALA PDT, although 4 lesions recurred over 12 months. In 3 patients with multiple BCCs, PDT cleared 52 (90%) of 58 lesions, with 2 recurrences during 41 months (range, 12-52 months). Treatments were well tolerated, with only 5 patients with solitary large lesions requiring local anesthesia. CONCLUSIONS: delta-Aminolevulinic acid PDT is an effective tissue-sparing modality achieving good cosmesis. We propose that delta-ALA PDT be considered as a first-line therapy for large and/or multiple areas of Bowen disease and superficial BCCs.
Description
Date
2001-03
Publisher
Collections
Keywords
Cancer Recurrence
Multiple Primary Cancer
Skin Cancer
Multiple Primary Cancer
Skin Cancer
Type
Article
Citation
Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. 2001, 137 (3):319-24 Arch Dermatol